唐氏综合征儿科患者上气道刺激的滴定方案
该小队列研究在多学科协作下制定了一套针对唐氏综合征儿科患者上气道刺激(UAS)的标准化滴定多导睡眠图方案,纳入5例患者,术后按预设时间点完成滴定,所有患者呼吸暂停低通气指数(AHI)较基线下降且每晚设备使用超过6小时,耐受良好。
要点
- 针对唐氏综合征儿科患者制定UAS标准化滴定多导睡眠图方案,含初始激活当晚及术后1、2-3、6、12个月滴定。
- 5例患者均完成预定时间点滴定,全部患者AHI较基线下降且每晚设备使用超过6小时。
- 作者认为该方案可作为其他机构建立儿科唐氏综合征UAS滴定项目的模型。
核心结论
- 针对唐氏综合征儿科患者的标准化UAS滴定多导睡眠图方案促进适应并优化AHI下降,在该人群中显示UAS有效。
研究设计与样本
- 小队列研究,纳入2022年6月至2024年1月期间接受UAS滴定的唐氏综合征合并持续阻塞性睡眠呼吸暂停的儿科患者5例。
- 方案由三级儿童医院的多学科协作制定,该院设有专门的儿科多导睡眠图实验室。
- 首次滴定多导睡眠图在设备激活当晚进行,后续滴定在植入后1个月、2至3个月、6个月和12个月进行。
主要发现
- 5例患者中3例为男性,4例自报为白人;植入时中位(范围)年龄为15岁(12-20岁)。
- 术前中位(范围)AHI为20.1(15.6-38.8)。
- 植入后1个月UAS滴定的中位(范围)起始电压为1.7 V(0.4-1.7 V)。
- 所有5例患者均完成上述术后时间点的UAS滴定多导睡眠图,全部患者AHI较基线下降且耐受良好(即每晚设备使用超过6小时)。
关键数值与推荐
- 初始滴定目标是适应,在后续多导睡眠图中促进AHI优化。
- 提供了一份UAS滴定方案、样本多导睡眠图报告表以及面向睡眠技师的一般信息。
临床怎么用
- 作者认为该方案可作为其他机构建立唐氏综合征儿科患者UAS滴定项目的模型。
- 作者指出随着更多儿科患者植入UAS设备,方案可进一步完善以确保最佳结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Upper airway stimulation (UAS) was recently approved to treat persistent obstructive sleep apnea in pediatric patients with Down syndrome. Appropriate titration of the UAS implantable device is essential to achieve optimal outcomes, but standardized titration protocols for young patients are lacking. OBJECTIVE: To develop and share a UAS titration protocol for pediatric patients with Down syndrome. DESIGN, SETTING, AND PARTICIPANTS: This small cohort study of pediatric patients with Down syndrome presents a standardized UAS stimulation titration protocol for conducting postimplantation polysomnograms. The protocol was developed through a multidisciplinary collaboration at a tertiary children's hospital with a dedicated pediatric polysomnogram laboratory. The initial titration polysomnogram was performed on the night of device activation, with subsequent titration polysomnograms performed at 1 month, 2 to 3 months, 6 months, and 12 months after implantation. The initial titration goal is acclimation, promoting AHI optimization in later polysomnograms. Pediatric patients with Down syndrome and persistent obstructive sleep apnea who have undergone UAS titration from June 2022 to January 2024 participated in this study. EXPOSURE: A novel standardized UAS titration polysomnogram protocol. MAIN OUTCOMES AND MEASURES: The main outcomes were apnea-hypopnea index (AHI) change and nightly device use in hours. RESULTS: This study included 5 pediatric patients with Down syndrome who have undergone UAS implantation. Three patients were male, and 4 identified as White. The median (range) age at implantation was 15 years (12-20 years), and the median (range) preoperative AHI was 20.1 (15.6-38.8). The median (range) incoming voltage for a 1-month postimplant UAS titration polysomnogram was 1.7 V (0.4-1.7 V). All 5 patients completed UAS titration polysomnograms at the aforementioned postoperative time course; all patients also experienced an AHI reduction from baseline and adequate tolerance of UAS (ie, nightly device use of more than 6 hours). A titration protocol for UAS in pediatric patients with Down syndrome, a sample polysomnogram report form, and general information for sleep technologists are provided. CONCLUSIONS AND RELEVANCE: In this study, a standardized UAS protocol for device titration during polysomnogram promoting acclimation and optimized AHI reduction demonstrated UAS efficacy in pediatric patients with Down syndrome. The protocol can be used as a model for other institutions creating programs for UAS titration in pediatric patients with Down syndrome. As more pediatric patients undergo UAS device implants, protocols can be refined to ensure optimal outcomes.
引用
- Frederick RM, Baldassari CM. Titration Protocol for Upper Airway Stimulation in Pediatric Patients With Down Syndrome. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 39480464. doi:10.1001/jamaoto.2024.3701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。